Our mission: To develop novel precision drugs targeting the tumor stroma
We envision a new era when cancer will be beaten with orchestrated combinations of precision drugs. Both tumor epithelial cells and the tumor microenvironment will be targeted, to block tumor growth, metastasis, immune suppression and drug resistance.
Since war was declared on cancer forty-five years ago, significant advances have been achieved in the prevention and treatment of early stages of cancer. However, little progress has been made in the development of efficient tools to fight late and invasive stages of cancer.
The battlefield must be broaden to develop precision drugs that target not only the tumor epithelial cells, but also the tumor microenvironment, the tumor-associated stroma: A complex, heterogeneous network of extracellular matrix, soluble cytokines, chemokines, and proteases, cancer-associated fibroblasts, endothelial and haematopoietic cells, which play a key role in tumor invasion, angiogenesis, metastasis, drug resistance and immune suppression.
Oncomatryx therapeutic approach is focused on the development of novel precision drugs that target proteins located in the tumor microenvironment. A novel route to cancer treatment, directed not against tumor epithelial cells, but the stromal cells that promote their invasiveness, immune suppression and drug resistance.
We have developed a comprehensive pipeline of therapeutic antibodies, antibody-drug conjugates and human-derived proteins that target the tumor-associated stroma.
Diagnostic and companion diagnostic products have also been developed, to diagnose and prognose tumor invasiveness, as well as select and monitor the patients to receive Oncomatryx stroma-targeted precision drugs, from clinical trials stage on.